Maggie L. Shaw

Byoung Chul Cho, MD, PhD, of the Yonsei University College of Medicine, discussed outcomes in the COCOON trial of an enhanced dermatologic regimen with amivantamab-lazertinib treatment.

A new FDA-approved blood test for Alzheimer disease could transform diagnosis and treatment accessibility, according to this conversation with Howard Fillit, MD, and Anthony “Nino” Sireci, MD, MSc.

New guidelines and advocacy enhance myasthenia gravis treatment access, promoting proactive management and improved insurance coverage for diverse patient populations.

Despite overall growth in the radiology workforce, the proportion of pediatric radiologists specifically decreased from 2016 to 2023.

The FDA's removal of REMS for CAR T-cell therapies enhances access for community oncology, paving the way for innovative treatments and improved patient outcomes.

Monthly SC amivantamab plus daily lazertinib demonstrated strong efficacy and tolerability in EGFR-mutated advanced NSCLC, providing a convenient alternative to IV dosing.

A study finds stronger CV protection from glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in patients with higher BMI, with kidney benefits consistent across all groups.

Cemiplimab shows significant survival benefits over chemotherapy for advanced non–small cell lung cancer (NSCLC) with high PD-L1 expression, enhancing treatment outcomes.

Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.

Efren Flores, MD, of Harvard Medical School and Massachusetts General Hospital, discussed the findings of a subanalysis of the Screen ASSIST tobacco cessation clinical trial.

Oranus Mohammadi, MD, outlines how antibody-drug conjugates are transforming breast cancer treatment across subtypes and discusses her approach to sequencing high-cost targeted therapies within payer and clinical practice constraints.

Discontinuing dupilumab for atopic dermatitis (AD) may increase relapse risk, which requires ongoing management and tailored treatment strategies to manage that risk.

Maintaining eye health through regulating use of technology and attending annual checkups are an important aspect of children’s health as the school year approaches.

Emma Guttman-Yassky, MD, PhD, discusses promising hair regrowth results for alopecia areata treatments, emphasizing safety and rapid efficacy.

Methotrexate significantly lowered systolic blood pressure compared with sulfasalazine in adults with newly diagnosed rheumatoid arthritis, suggesting potential cardiovascular benefits beyond its anti-inflammatory effects.

New abstracts from the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025 found that ACC017 showed promise in its use as an antiretroviral therapy.

Oranus Mohammadi, MD, discusses the emerging applications of circulating tumor DNA (ctDNA) in breast cancer care and emphasizes the importance of clear communication to help patients navigate uncertain or anxiety-provoking biomarker test results.

Long-term follow-up data on the use of BCMA-directed RNA chimeric antigen receptor T-cell therapy (CAR T) for refractory generalized myasthenia gravis show patient outcomes at 2, 3, 6, 9, and 12 months.

Rising cases of accidental nicotine exposure in children prompt an FDA warning and safety call to manufacturers.

In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.

Patients had better linkage to care for HIV and HIV was more frequently diagnosed when it was tested alongside other sexually transmitted infections (STIs), such as chlamydia and gonorrhea.

Rusfertide has received orphan drug, fast track, and breakthrough therapy designations from the FDA, and in this interview, Andrew Kuykendall, MD, Moffitt Cancer Center, emphasizes the critical need for therapies that offer a sense of normalcy to individuals with polycythemia vera.

Ovarian cancer deaths remain uneven across age, geography, and racial and ethnic groups, highlighting the need for targeted interventions.

Why is health care so staggeringly difficult to use? How do we fix it? To move forward, we first must look back, because the system we have today was not really designed, it evolved, notes Ariela Simerman, Turquoise Health.

Joanne Mortimer, MD, FACP, FASCO, discusses the practical applications and limitations of circulating tumor DNA (ctDNA) testing in breast cancer, highlighting its role in guiding targeted therapy, challenges in patient communication and payer coverage, and unique barriers for male patients.

Jorge Nieva, MD, explores the challenges of translating biomarker testing into treatment decisions for non–small cell lung cancer (NSCLC), the role of repeat testing in detecting resistance mutations, and the importance of equitable access to molecular diagnostics in value-based care settings.

Close to 40% of patients with right heart failure and pulmonary arterial hypertension (PAH) who remain critically ill and require admittance to the intensive care unit die within 1 year of that hospitalization.

Givinostat shows promise in delaying Duchenne muscular dystrophy (DMD) progression, enhancing mobility, and maintaining safety in long-term treatment.

Chris Johnson, MBA, discusses how the Medicaid cuts could affect children's eligibility to receive health care.

Jorge Nieva, MD, highlights the critical role of molecular testing in non–small cell lung cancer (NSCLC) care, while addressing barriers such as limited tissue samples, delayed turnaround times, and the need for faster, more accessible diagnostic technologies.